Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Regeneron To Acquire Decibel Therapeutics At $4.00 Per Share Payable In Cash At Closing, With Additional Non-Tradeable Contingent Value Right To Receive Up To $3.50 Per Share In Cash

Author: Benzinga Newsdesk | August 09, 2023 07:35am

The proposed acquisition values Decibel at a total equity value of approximately $109 million based on the amount payable at closing, and a total equity value of up to approximately $213 million if the CVR milestones are achieved.

Posted In: DBTX REGN